Related Experiment Video
Updated: Oct 23, 2025
07:55
Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
Published on: April 11, 2018
14.6K
Establishment of an Academic Tissue Microarray Platform as a Tool for Soft Tissue Sarcoma Research
Che-Jui Lee1, Agnieszka Wozniak1, Thomas Van Cann1,2
1Laboratory of Experimental Oncology, Department of Oncology, KU Leuven, Leuven, Belgium.
Sarcoma
|August 20, 2021
Summary
This study details the creation of extensive soft tissue sarcoma (STS) tissue microarrays (TMAs) for rare cancer research. These TMAs enable efficient molecular and morphological characterization to identify new diagnostic markers and drug targets.
Area of Science:
- Oncology
- Pathology
- Biotechnology
Background:
- Soft tissue sarcoma (STS) is a rare and diverse group of mesenchymal tumors.
- Research into rare diseases like STS is often limited by sample availability and cost.
- Tissue microarrays (TMAs) offer an efficient method for studying rare diseases by consolidating multiple tissue samples.
Purpose of the Study:
- To establish a comprehensive tissue microarray (TMA) platform for soft tissue sarcoma (STS) research.
- To facilitate efficient and cost-effective morphological, immunohistochemical, and molecular characterization of STS subtypes.
- To support the identification of novel diagnostic markers and therapeutic targets for STS.
Main Methods:
- Archival tumor material from STS patients was collected starting in 2015.
- Well-annotated specimens included histopathological diagnosis, treatment, and clinical follow-up data.
- Duplicate or triplicate 1.0-1.5 mm tissue cores from representative tumor areas were selected by pathologists and assembled into TMA blocks using TMA Grand Master (3DHistech).
- Disease-specific TMAs were created for 7 STS subtypes, and a multisarcoma TMA was constructed for screening diverse subtypes.
Main Results:
- Established disease-specific TMAs for 7 STS subtypes: gastrointestinal stromal tumor, alveolar soft part sarcoma, clear cell sarcoma, leiomyosarcoma, liposarcoma, inflammatory myofibroblastic tumor, and alveolar rhabdomyosarcoma.
- Constructed a multisarcoma TMA with 7-11 cases per subtype, including angiosarcoma, dedifferentiated liposarcoma, pleomorphic liposarcoma, myxoid liposarcoma, leiomyosarcoma, malignant peripheral nerve sheath tumor, myxofibrosarcoma, rhabdomyosarcoma, synovial sarcoma, and undifferentiated pleomorphic sarcoma.
- The STS TMA platform is currently being expanded with additional sarcoma entities.
Conclusions:
- The developed STS TMA platform provides a valuable resource for the rapid and cost-effective characterization of various sarcoma subtypes.
- This platform is suitable for identifying potential novel diagnostic markers and drug targets in soft tissue sarcomas.
- The TMA resource is available for collaborative research projects to advance STS understanding and treatment.
